[The hypereosinophilic syndrome].
D000284:Administration, Oral; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D003937:Diagnosis, Differential; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage / Q000627:therapeutic use; D017681:Hypereosinophilic Syndrome / Q000145:classification / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use; D012307:Risk Factors; D012871:Skin Diseases / Q000175:diagnosis / Q000209:etiology
D000305:Adrenal Cortex Hormones; D000970:Antineoplastic Agents; D007155:Immunologic Factors; D016898:Interferon-alpha; D006918:Hydroxyurea
Le syndrome hyperéosinophilique.